Article
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
The Lancet. Oncology - 1 Aug 2024
Wu Yi-Long, Guarneri Valentina, Voon Pei Jye, Lim Boon Khaw, Yang Jin-Ji, Wislez Marie, Huang Cheng, Liam Chong Kin, Mazieres Julien, Tho Lye Mun, Hayashi Hidetoshi, Nhung Nguyen Viet, Chia Puey Ling, de Marinis Filippo, Raskin Jo, Zhou Qinghua, Finocchiaro Giovanna, Le Anh Tuan, Wang Jialei, Dooms Christophe, Kato Terufumi, Nadal Ernest, Hin How Soon, Smit Egbert F, Wermke Martin, Tan Daniel, Morise Masahiro, O'Brate Aurora, Adrian Svenja, Pfeiffer Boris M, Stroh Christopher, Juraeva Dilafruz, Strotmann Rainer, Goteti Kosalaram, Berghoff Karin, Ellers-Lenz Barbara, Karachaliou Niki, Le Xiuning, Kim Tae Min
Abstract excerpt
BACKGROUND: Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) and MET amplification as a mechanism of resistance to first-line osimertinib have few treatment options. Here, we report the primary analysis of the phase 2 INSIGHT 2 study evaluating tepotinib, a highly selective MET inhibitor, combined with osimertinib in this population. METHODS: This open-label, phase 2 study was conducted at 179...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.